Skip to main content
    S

    Spyre Therapeutics Inc. (SYRE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $93.81
    -5.56 (-5.60%)

    Market Cap: $9.44B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Spyre Therapeutics Inc. (SYRE) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Spyre Therapeutics (SYRE) has a market cap of $9.44B and an enterprise value of $9.35B. It kept -291.57% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 0.88% below the market cap, as cash exceeds debt.

    Market Cap$9.44B
    Enterprise Value$9.35B
    Latest price (Nov 17, 2026)$93.81

    Key Dates

    The next earnings report is expected on Feb 17, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 17, 2027 (expected)
    Last Earnings DateNov 3, 2026
    Fiscal Year EndDecember

    Price Statistics

    The stock is up 299.19% over 52 weeks and trades 2.25% above its 50-day average.

    Beta (1Y)1.70
    52-Week Change+299.19%
    1-Month Change+10.73%
    3-Month Change-13.87%
    6-Month Change+40.81%
    5-Year Change-47.23%
    10-Year Change-27.94%
    Total Return (1Y)+299.19%
    Total Return (3Y CAGR)+109.14%
    Total Return (5Y CAGR)-10.55%
    Return vs SPY (1Y)+277.69%
    Max Drawdown (1Y)-27.81%
    Max Drawdown (3Y)-73.99%
    Sharpe Ratio (1Y)2.08
    Correlation with SPY (1Y)0.36
    50-Day Average$91.75
    200-Day Average$77.31
    52-Week Range$23.01 to $110.64
    RSI (14 Days)46.2
    Average Volume (20 Days)943.54K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 27.40x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio27.40x
    Quick Ratio27.40x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -25.09% over the last 12 months, against a 5-year average of -98.20%.

    Return on Equity (ROE)-25.09%
    Return on Assets (ROA)-23.99%
    ROE (5Y Average)-98.20%
    ROA (5Y Average)-66.18%
    ROIC (5Y Average)-25.18%
    Asset Turnover0.11x

    Scores

    SYRE has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $90.49M over the last 12 months.

    Revenue$90.49M
    Gross Profit$45.25M
    Operating Income-$250.17M
    Pretax Income-$263.86M
    Net Income-$263.86M
    Reported EPS (TTM)-$2.78

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 95.45% of the $1.10B in total assets.

    Cash and Equivalents$82.73M
    Total Debt$0
    Net Cash$82.73M
    Working Capital$1.06B
    Shareholder Equity$1.05B
    Total Assets$1.10B
    Total Liabilities$48.19M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$249.32M
    FCF Per Share-$2.67
    Depreciation and Amortization$11.58M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -276.45%.

    Gross Margin50.00%
    Operating Margin-276.45%
    Pretax Margin-291.57%
    Net Margin-291.57%

    Stock Splits

    The last split was a 1-for-25 reverse split on Sep 8, 2023.

    Last Split DateSep 8, 2023
    Split TypeReverse split
    Split Ratio1:25

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About SYRE

    What is SYRE's market cap?

    Spyre Therapeutics has a market cap of $9.44B. Its enterprise value, which adds debt and subtracts cash, is $9.35B.

    Does SYRE pay a dividend?

    No. Spyre Therapeutics does not pay a dividend.

    How much debt does SYRE have?

    Spyre Therapeutics has $0 of total debt and $82.73M of cash and equivalents, a net cash position of $82.73M.